Dr Andrew Schaefer is a researcher at Newcastle University specializing in mitochondrial genetics and neurogenetics. His work focuses on understanding the clinical and molecular mechanisms of mitochondrial DNA (mtDNA) disorders, particularly autosomal recessive POLG disease, dysferlinopathy, and mtDNA maintenance syndromes. He has contributed to studies on disease progression, genotype-phenotype correlations, and diagnostic methodologies in mitochondrial myopathy and encephalopathy. Key research areas: Mitochondrial Genetics, Neurodegenerative Diseases, Molecular Genetics, Clinical Neurology Publication Trends: His 15 most recent articles (2018–2022) emphasize mitochondrial DNA mutations (e.g., POLG, MT-ND5, DYSF) and their links to neurological conditions like Parkinsonism, ataxia, and myopathy. Collaborations span neurology, cardiology, and genetics. Notable Contributions: Pioneered research on stroke-like episodes in mitochondrial disease, cardiac manifestations of mtDNA disorders, and biomarker development (e.g., height as a disease severity indicator). His work bridges clinical observations with molecular diagnostics.
Deepa Ramachandran is an Instructional Assistant Professor in the Department of Electrical and Computer Engineering at the University of Houston's Cullen College of Engineering. Her research focuses on computational modeling of biological systems, with notable contributions to cardiovascular modeling and MEMS-enabled RF circuit design. She holds a Ph.D. in Electrical and Computer Engineering from Rice University. Education: Ph.D., Electrical and Computer Engineering, Rice University Research Interests: Dr. Ramachandran specializes in interdisciplinary biomedical engineering, developing computational models to study ventricular mechanics in heart disease and treatment interactions. Her work also extends to reconfigurable RF circuits using MEMS technology for applications in spectrum sensing and wireless communication. Publications Overview: Her research spans 2003–2011, with key contributions in cardiovascular modeling (e.g., cardiac tamponade characterization, rotary blood pump interactions) and MEMS-based RF systems (e.g., frequency-hopping filters, low-power VCO designs). These studies bridge biomedical and electrical engineering domains, emphasizing clinical applications and adaptive electronics. Affiliations & Contact: Office: KAB1 307E Email: dpr2@uh.edu
Allan Thomas Højland is a Clinical Associate Professor at Aalborg University Hospital under Aalborg University's Faculty of Medicine , specializing in Clinical Genetics . His work bridges clinical practice and genetic research, focusing on hereditary hearing impairments. Current affiliation: Aalborg University Hospital, Department of Clinical Genetics Academic field: Human genetics, otosclerosis, exome sequencing Research trends indicate expertise in: Hereditary hearing loss mechanisms Monogenic and polygenic inheritance patterns Otosclerosis genetic susceptibility Genetic variant classification Clinical gene panel applications Extracellular matrix protein genetics Collaborations span multidisciplinary teams in Europe, with publications in European Journal of Human Genetics , Human Genetics , and Molecular Genetics and Genomic Medicine .
Suneet Agarwal, MD, PhD, is Associate Professor of Pediatrics at Harvard Medical School and Co-Program Leader for the Stem Cell Transplant Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. His work bridges clinical pediatrics, hematology-oncology, and translational research in bone marrow failure and telomere biology disorders. Medical School: Harvard Medical School, 2001 Internship: Boston Children's Hospital, 2002 Residency: Pediatrics, Boston Combined Residency Program (BCRP), 2003 Fellowship: Pediatric Hematology-Oncology, Dana Farber Cancer Institute/Children's Hospital Boston, 2006 Dr. Agarwal’s research focuses on telomere biology disorders , mitochondrial DNA deletion disorders , and inherited bone marrow failure syndromes . He employs induced pluripotent stem cells (iPSCs), gene editing, and molecular techniques to model diseases and develop therapies, including small-molecule PAPD5 inhibitors for telomere restoration. His lab investigates nucleotide metabolism, telomere length control, and heteroplasmy dynamics in mitochondrial disorders. His recent publications reveal a strong thematic focus on telomere regulation, stem cell biology, and hematopoietic transplantation. Key trends include the role of nucleotide salvage in telomere maintenance, molecular mechanisms of telomere disease, and clinical outcomes in stem cell transplant for myelodysplastic syndrome and telomere disorders. His work frequently appears in top-tier journals such as Nature Genetics , Cell Stem Cell , and Blood . Scientific contributions include: Discovery of PAPD5 inhibitors that restore telomerase activity in patient stem cells Mechanistic insights into TERC and TERT variants in telomere diseases Characterization of liver and vascular complications in dyskeratosis congenita Development of iPSC models for rare genetic blood disorders Dr. Agarwal leads a research lab at Dana-Farber/Boston Children's and is actively involved in mentoring and scientific innovation. He has not publicly listed specific advisees or awards, but his research program is supported by extensive publications and clinical leadership. He is not indicated to be part-time, retired, or deceased. His laboratory, the Suneet Agarwal Lab , is dedicated to understanding the molecular basis of genetic blood disorders and developing regenerative and pharmacological therapies. The lab utilizes cutting-edge technologies including single-cell multi-omics, genome editing, and stem cell reprogramming to uncover disease mechanisms and therapeutic targets.
Deborah Orel-Bixler serves as Professor of Clinical Optometry and Vision Science at the University of California, Berkeley's School of Optometry, where she holds dual leadership roles as Chief of the Infant Toddler Clinic and Chief of the SVACH Clinic. Her clinical responsibilities focus on specialized vision care for pediatric and multi-disabled populations within the university's academic medical framework. Her educational credentials include a Doctor of Optometry (OD) and Doctor of Philosophy (PhD), with doctoral research completed at UC Berkeley in 1989. The dissertation, titled Subjective and Visual Evoked Potential measures of acuity in normal and amblyopic adults and children , established her foundational work in visual assessment methodologies. Dr. Orel-Bixler's research program centers on pediatric vision science with three interconnected pillars: developing vision assessment protocols for infants with severe disabilities, validating acuity testing methods for preschool populations, and investigating neural mechanisms in strabismus. Her work bridges clinical optometry and neuroscience, particularly through visual evoked potential (VEP) studies, to address critical gaps in early vision impairment detection. This trajectory reflects a consistent commitment to translating laboratory findings into practical screening tools for vulnerable pediatric groups. Analysis of her publication history reveals sustained focus on optimizing vision screening for preschoolers, demonstrated by leadership in the multi-institutional Vision in Preschoolers (VIP) Study Group. Her research established evidence-based standards for HOTV and Lea symbols testing while pioneering electronic acuity assessment methods. The longitudinal nature of her work—from infantile esotropia neurophysiology (1990s) to preschool screening validation (2000s)—shows methodological evolution toward population-level impact while maintaining clinical relevance. Her professional recognition includes: Fellow of the American Academy of Optometry (FAAO) Dr. Orel-Bixler has directed major clinical initiatives including the Infant Toddler Clinic and SVACH Clinic, indicating significant administrative responsibilities alongside research leadership in the VIP Study Group. While specific grant histories aren't detailed in source materials, her 15+ peer-reviewed publications in journals like Optometry and Vision Science and Investigative Ophthalmology & Visual Science demonstrate sustained research productivity. She has also developed applied resources including the Vision Tests for Infants video/booklet series and contributed foundational chapters to Rudolph's Pediatrics . Her clinical leadership positions at UC Berkeley indicate active involvement in training through direct supervision in specialized clinics, though formal mentoring roles aren't explicitly documented. The integration of her research on multi-disabled infant assessment with clinical SVACH Clinic operations demonstrates a cohesive approach to addressing complex vision care needs within academic medicine.
Dr. Robert James Adam serves as a Senior Lecturer and Clinical Trials Specialist at the University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine. He is a behavioural neurologist specializing in cognition and movement disorders, with clinical leadership roles in deep brain stimulation at The Royal Brisbane & Women's Hospital and statewide services for Huntington's Disease, Friedreich's Ataxia, and Parkinson's Disease. His research spans clinical trials of novel therapies for neurodegenerative disorders, particularly antisense oligonucleotides for Huntington's Disease (PRECISION-HD trials) and drug repurposing in Parkinson's Disease. Collaborating across UQ and national networks, his work integrates clinical neuroscience with molecular immunology, neuroimaging, and cognitive assessment. Recent publications reveal strong focus on biomarker discovery, diagnostic accuracy in dementia, and neuromodulation mechanisms. Dr. Adam contributes to national initiatives including the NHMRC-funded Australian Dementia Network (ADNet) and previously served as research officer in the Prospective Imaging Study of Ageing (PISA). His academic leadership extends to medical education for undergraduates and graduates, alongside supervision of higher degree candidates. Principal Investigator: PRECISION-HD1 & 2 clinical trials for Huntington's Disease Clinical Lead: Metro North Deep Brain Stimulation Program Statewide Service Lead: Huntington's Disease and Friedreich's Ataxia Collaborator: Nationwide Parkinson's drug repurposing initiative His clinical expertise is complemented by extensive international training across neurology centers in the US, UK, and Australia, with ongoing commitment to translating research into improved patient care pathways for movement and cognitive disorders.
Professor Hanns Lochmuller is a leading researcher in rare neuromuscular and genetic disorders at Newcastle University. His work bridges clinical practice and genomic research, focusing on improving diagnosis and therapeutic interventions for patients with complex inherited conditions. His research spans: Genomic diagnostics for spinal muscular atrophy and rare diseases Molecular mechanisms of GNE myopathy, mitochondrial disorders, and congenital myopathies Biomarker discovery using lipidomics and circulating RNA Clinical trial development for neuromuscular therapeutics European collaborative networks for rare disease diagnosis Analysis of his 2020-2025 publications reveals three dominant trends: 1) Advanced genomic reanalysis techniques uncovering missed diagnoses, 2) Metabolomic and biomarker studies for disease progression tracking, and 3) Rigorous clinical trial frameworks for emerging therapies. His work consistently emphasizes translational applications, with over 60% of recent studies involving multi-center European collaborations addressing diagnostic gaps and therapeutic development. Lochmuller actively supervises research teams across Newcastle University's clinical departments, with publications indicating leadership in major observational studies like the 3-year GNE Myopathy Monitoring Program. His work frequently secures funding for pan-European rare disease initiatives, though specific grant details aren't provided in this dataset.
Melinda S. Burnett, MD is an Associate Professor of Neurology at Creighton University School of Medicine in Omaha, Nebraska, serving as Clerkship Director for the Neurology M3 Clerkship and Neurology Clerkship Site Director. A board-certified movement disorders specialist, she treats Parkinson's disease, tremor, gait disorders, ataxia, and dystonia while leading medical education initiatives in neurology. Her educational journey includes: Medical Degree: University of California, San Francisco, School of Medicine Doris Duke Clinical Research Fellowship Neurology Residency: Mayo Clinic (Rochester, MN) with Chief Resident role Movement Disorders Fellowship: Mayo Clinic Movement Disorders Research Fellowship: Royal Brisbane & Women’s Hospital, Australia Dr. Burnett's research centers on movement disorder pathophysiology and clinical management, with emphasis on Parkinson's disease mechanisms, gait/ataxia diagnostics, and botulinum toxin therapeutics. Her work bridges translational research and medical education, developing innovative teaching methodologies for neurological conditions. She actively investigates exercise-induced movement disorders in athletes and rare ataxia presentations. Her publication portfolio demonstrates consistent focus on movement disorder complexities, particularly in genetic ataxias and therapeutic interventions. Key themes include neurological mimics, deep brain stimulation optimization, and clinical manifestations of movement disorders across diverse patient populations. The work consistently targets practical clinical applications for neurologists. Her accolades reflect dual excellence in research and teaching: First Melvin Yahr International Young Scientist Award for Brain and Movement Disorders Research Mayo Clinic Golden Apple Teaching Award (2018-2019) Creighton Medical School Golden Apple Award for Excellence in Teaching (2019) As Clerkship Director, Dr. Burnett shapes neurology education for medical students through curriculum development and clinical supervision. She mentors residents in the Neurology Residency Program and presents regularly at grand rounds and national conferences. Her educational impact extends through the Movement Neurophysiology Lab where she integrates clinical practice with teaching. She directs the Movement Neurophysiology Lab and collaborates within Creighton's Neurology Residency Program. Her clinical work at Immanuel Neurological Institute informs both patient care and educational frameworks, maintaining strong ties with the International Parkinson and Movement Disorders Society and American Neurological Association.
Eirik Frengen is a Professor at the Department of Medical Genetics, Oslo University Hospital (OUS). His research focuses on identifying disease-causing genomic variations in patients with rare neurological diseases and syndromes, using cell cultures and model organisms to elucidate molecular disease mechanisms. He has been employed at the University of Oslo (UiO) since 2005 and served as Section Head (2010-2017) and Senior Researcher (2017->) at OUS. He holds a Dr.scient degree (1993) and Cand.scient (1989) in molecular and general genetics from UiO. His research involves characterizing genomic variations in rare neurological conditions and connecting gene defects to clinical features. He has supervised 11 PhD students (7 as main supervisor), 3 research students, and 23 MSc students. His publications span topics like ciliopathies, leukodystrophy, intellectual disability, and genomic deletions/duplications. Recent articles (2024-2019) explore NAV3 variants in developmental delay, STIM1 mutations in Stormorken syndrome, and genomic mechanisms in Strømme syndrome. Keywords include Genetics, Neurology, Molecular Biology, and Developmental Disorders. Subfields cover topics like intellectual disability, microcephaly, calcium signaling, and ciliopathy.
Sam McLenachan is an Adjunct Senior Research Fellow at the University of Western Australia (UWA), affiliated with the UWA Medical School and the Centre for Ophthalmology and Visual Science (linked to the Lions Eye Institute). His research focuses on stem cell biology, retinal diseases, and genetic disorders, with a particular emphasis on induced pluripotent stem cells (iPSCs) and their applications in clinical settings. Key research interests include the generation and use of iPSC lines for studying retinal dystrophies (e.g., PRPF31 mutations), nanoparticle-based gene therapy for retinal delivery, and optimizing stem cell-derived therapies for ocular conditions. He has contributed to projects addressing splice-altering mutations in inherited retinal diseases and personalized disease modeling. Notable grants include leadership roles in NHMRC-funded initiatives and collaborations with institutions like Retina Australia. His work aligns with UN Sustainable Development Goals related to health and well-being (SDG 3). McLenachan has published extensively in journals such as Stem Cell Research and Journal of Drug Targeting , with a focus on advancing regenerative medicine and therapeutic strategies for genetic eye disorders.
Dr. Nivedita Patni is an academic researcher and clinician at UT Southwestern Medical Center’s Department of Pediatrics, affiliated with the Center for Human Nutrition. She holds a medical degree from All-India Institute of Medical Sciences (AIIMS) and completed pediatric residency at Miami Children’s Hospital, followed by a pediatric endocrinology fellowship at UT Southwestern. Her clinical practice focuses on pediatric lipid disorders, including genetic dyslipidemias like type 1 hyperlipoproteinemia (T1HLP) and rare syndromes such as lipodystrophy and progeria. Her research investigates the genetic basis of lipid disorders, genotype-phenotype relationships, and clinical management strategies for pediatric patients. Notable contributions include pioneering a randomized clinical trial of orlistat for T1HLP and describing novel lipodystrophy syndromes linked to LMNA gene mutations. She has authored over 30 peer-reviewed articles, emphasizing pediatric dyslipidemia management, caveolar dysfunction mechanisms, and metabolic complications in rare disorders. Key article trends reveal a focus on translational research, integrating genetic insights with clinical practice. Her work bridges endocrinology and metabolism, addressing unmet needs in rare disease diagnosis and therapy. No formal awards are listed, but her contributions are highlighted through collaborative efforts with institutions like the National Lipid Association. Dr. Patni’s research is conducted at the Center for Human Nutrition, where she explores the natural history and physiology of lipodystrophies. Her work emphasizes interdisciplinary collaboration to advance understanding of lipid metabolism and its systemic impacts. No formal grants or student advisement details are provided, but her publications reflect active engagement in clinical trials and case-based investigations.
Dr. Yitzchak Goldstein is an Associate Professor in the Department of Pathology at Albert Einstein College of Medicine. He trained at Einstein for medical school, completed residency and chief residency in anatomic and clinical pathology at Montefiore Medical Center, and pursued a fellowship in molecular genetic pathology at Mount Sinai Hospital. His expertise spans molecular diagnostics, clinical laboratory optimization, and data analysis. He currently serves as Associate Director of Molecular Infectious Disease Testing and Co-Director of Molecular Genetic Laboratories at Montefiore. Education: Medical School: Albert Einstein College of Medicine Residency/Chief Residency: Montefiore Medical Center (Anatomic and Clinical Pathology) Fellowship: Molecular Genetic Pathology at Mount Sinai Hospital Research Focus: Advanced molecular diagnostics, laboratory efficiency, and diagnostic data analysis with emphasis on infectious disease testing and genetic pathology. Teaching Awards: Leo M. Davidoff Award (Einstein) and Montefiore Pathology Resident Teaching Award. Lab Leadership: Directs molecular diagnostics for infectious diseases and co-leads genetic pathology laboratories at Montefiore.
Burcu Türkgenç is an Assistant Professor in the Department of Medical Biology at Üsküdar University’s Faculty of Medicine. She earned her PhD in Medical Biology and Genetics from Marmara University (2016), preceded by a Master’s in Biotechnology (Hacettepe University, 2007) and a Bachelor’s in Biology (Hacettepe University, 2003). Her career includes roles as a project assistant at Hacettepe University’s Gene Mapping Lab (2004) and a molecular biologist in genetic diagnosis centers (2007–2021). She became an Assistant Professor in 2021. Her research focuses on human genetics, particularly cardiogenetics, immunogenetics, neurogenetics, and infertility-related disorders. Notable works include studies on SMN2 gene deletions in spinal muscular atrophy (2024) and MEFV gene variants in Turkish populations (2022). She has supervised two Master’s theses (2024) and contributed to over 14 Scopus-indexed publications. Education: BSc Biology, Hacettepe University (2003) MSc Biotechnology, Hacettepe University (2007) PhD Medical Biology and Genetics, Marmara University (2016) Administratively, she serves as Head of the Department of Medical Biology, Erasmus Coordinator, and Course Coordinator. She received the TEKNOFEST 2024 award for innovative ALS treatment approaches. Her teaching includes courses on immunology, cell biology, and genetic fundamentals. Key projects include studies on genetic markers in inguinoscrotal pathology (TÜBİTAK-funded) and Y-chromosome microdeletions in male infertility. She participates in the Neurogenetics Research Group and international academic committees.
Matthew Deardorff, MD, PhD serves as Professor of Pediatrics (Clinical Scholar) at the Keck School of Medicine, University of Southern California, with clinical and research appointments at Children's Hospital Los Angeles (CHLA). His work bridges clinical pediatrics and genomic medicine with a focus on constitutional genomic disorders. Dr. Deardorff's research centers on the genomic basis of neurodevelopmental disorders, particularly Cornelia de Lange syndrome and related cohesinopathies. His lab investigates copy number variant interpretation , genotype-phenotype correlations in diverse populations, and diagnostic yield improvement through novel genomic technologies. Recent work demonstrates expertise in optical genome mapping for constitutional variants and characterization of rare syndromes like KBG and FATCO. Analysis of his 15 most recent publications reveals strong emphasis on clinical genomic implementation , with 60% of 2023-2025 papers addressing diagnostic methodology improvements. His work consistently incorporates diverse cohort representation and phenotype-driven analysis , particularly examining how ethnic diversity impacts variant interpretation. Key technical contributions include droplet digital PCR for mosaic quantification and phenotypic predictors for RASopathy testing. Dr. Deardorff participates in major collaborative efforts including the international Cornelia de Lange syndrome consensus statement and NIH-funded genomic medicine initiatives. His leadership appears in multi-center studies focused on standardizing genomic diagnostics and improving variant classification systems. His clinical work involves directing genomic diagnostics for complex pediatric cases, particularly those with congenital anomalies and neurodevelopmental disorders. The research program maintains active collaborations with the Children's Hospital Los Angeles Center for Genetic Medicine and USC's Institute for Genetic Medicine.
Fatimah Albuainain is a Researcher in the Department of Clinical Genetics at Erasmus MC, specializing in genetic diagnostics and neurodevelopmental disorders research. Her work bridges clinical practice with advanced genomic technologies to identify genetic causes of rare diseases. Her primary research interests include: RNA Sequencing applications in clinical diagnostics Neurodevelopmental disorders and mental retardation genetics Genome sequencing and variant interpretation X-chromosome inactivation patterns Cytogenetic analysis of rare syndromes Gene deletion mechanisms Analysis of her recent publications reveals a strong focus on applying next-generation sequencing technologies to diagnose rare genetic conditions, with particular expertise in neurodevelopmental disorders. Her work demonstrates increasing clinical impact, with publications spanning from fundamental genetic mechanisms to potential therapeutic interventions as evidenced by the statin treatment research. She collaborates extensively with international research teams as shown by the large multi-institutional author lists on her publications, indicating strong networking within the global genetics community.
